Tasa de abandono por eventos adversos en el tratamiento

During the minimum treatment period of 52 weeks, 10.6% of patients discontinued therapy due to adverse events. A detailed analysis on potential drug-induced liver injury (DILI) did not reveal liver safety concerns.